A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of MRX-6 Cream 2% in Pediatric Subjects With Mild to Moderate Atopic Dermatitis Followed by an Open Label Extension

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of MRX-6 Cream 2% in Pediatric Subjects With Mild to Moderate Atopic Dermatitis Followed by an Open Label Extension

Discontinued
Phase of Trial: Phase II

Latest Information Update: 10 May 2016

At a glance

  • Drugs MRX 6 (Primary)
  • Indications Atopic dermatitis
  • Focus Therapeutic Use
  • Sponsors Celsus Therapeutics
  • Most Recent Events

    • 05 May 2016 Status changed from active, no longer recruiting to discontinued.
    • 17 Feb 2015 Status changed from recruiting to active, no longer recruiting, based on information in the Celsus Therapeutics media release.
    • 17 Feb 2015 Results published in the Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top